BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-1.89%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$14.7B
AUM Growth
+$14.7B
(-5.8%)
Cap. Flow
-$316M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4
Top Buys
| 1 |
BCEL
Atreca, Inc. Class A Common Stock
BCEL
|
$66.6M |
| 2 |
Adaptive Biotechnologies
ADPT
|
$56.3M |
| 3 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$29.4M |
| 4 |
Neurocrine Biosciences
NBIX
|
$26.7M |
| 5 |
Heron Therapeutics
HRTX
|
$18.6M |
Top Sells
| 1 |
Incyte
INCY
|
$195M |
| 2 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$97.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$68.7M |
| 4 |
GHDX
Genomic Health, Inc.
GHDX
|
$54.6M |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
$46M |
Sector Composition
| 1 | Healthcare | 94.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
26
DELISTED
Audentes Therapeutics, Inc
BOLD
| $57M | 0.39% |
1,506,438
-208,745
| -12% | -$7.9M |
|
|
27
Adaptive Biotechnologies
ADPT
$1.96B
| $56.3M | 0.38% |
+1,165,411
| New | +$56.3M |
|
28
BioCryst Pharmaceuticals
BCRX
$1.74B
| $54.5M | 0.37% |
14,382,673
-735,408
| -5% | -$2.79M |
|
|
RARX
29
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $54.2M | 0.37% |
1,801,695
+978,582
| +119% | +$29.4M |
|
|
MYOK
30
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $51M | 0.35% |
1,016,306
| – | – |
|
|
DBVT
31
DBV Technologies
DBVT
$249M
| $45.3M | 0.31% |
5,509,560
| – | – |
|
32
Krystal Biotech
KRYS
$4.35B
| $41.7M | 0.28% |
1,034,674
+250,000
| +32% | +$10.1M |
|
|
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
| $40.9M | 0.28% |
5,707,411
| – | – |
|
34
uniQure
QURE
$954M
| $40.5M | 0.28% |
517,700
-87,300
| -14% | -$6.82M |
|
35
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $37.9M | 0.26% |
2,799,577
-200,423
| -7% | -$2.71M |
|
36
Zymeworks
ZYME
$1.07B
| $37.6M | 0.26% |
1,708,472
| – | – |
|
37
Neurogene
NGNE
$284M
| $25.8M | 0.18% |
10,934,154
| – | – |
|
38
Axsome Therapeutics
AXSM
$6.09B
| $19.9M | 0.14% |
772,286
-427,714
| -36% | -$11M |
|
39
Xencor
XNCR
$594M
| $17.5M | 0.12% |
428,120
| – | – |
|
40
Merus
MRUS
$5.04B
| $17M | 0.12% |
1,160,014
| – | – |
|
|
ACOR
41
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $15.4M | 0.1% |
2,011,189
+1,719,055
| +588% | +$13.2M |
|
|
LJPC
42
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $14.4M | 0.1% |
1,559,231
+1,053,991
| +209% | +$9.75M |
|
|
AIMT
43
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $14M | 0.1% |
673,908
| – | – |
|
|
ACGN
44
DELISTED
Aceragen, Inc. Common Stock
ACGN
| $12.3M | 0.08% |
4,605,822
-234,073
| -5% | -$625K |
|
45
Protagonist Therapeutics
PTGX
$3.62B
| $12.1M | 0.08% |
995,082
+591,189
| +146% | +$7.16M |
|
46
Marker Therapeutics
MRKR
$11.2M
| $11.9M | 0.08% |
1,500,000
| – | – |
|
47
Spyre Therapeutics
SYRE
$1.02B
| $11.7M | 0.08% |
1,713,604
| – | – |
|
48
Assembly Biosciences
ASMB
$183M
| $10.8M | 0.07% |
803,246
+654,659
| +441% | +$8.83M |
|
49
Sangamo Therapeutics
SGMO
$161M
| $10.8M | 0.07% |
999,823
| – | – |
|
50
Catalyst Pharmaceutical
CPRX
$2.42B
| $9.83M | 0.07% |
2,559,461
-340,539
| -12% | -$1.31M |
|